Evidence map›Paper›PMID 35720056›Full record

ReviewDrugs in context2022

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour.

Yuliya Lytvyn, Muskaan Sachdeva, Asfandyar Mufti, Jensen Yeung

Open access · goldAbstract readReview
In one paragraph

Review in Drugs in context, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Psoriasis in People With Skin of Color: An Evidence-Based Update.International journal of dermatology · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Comorbidity Burden in Psoriasis Patients with Skin of Color.Journal of psoriasis and psoriatic arthritis · 2024
    Article
  9. Review
  10. Article
  11. Skin of colour: essentials for the non-dermatologist.Clinical medicine (London, England) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yuliya LytvynTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Muskaan SachdevaTemerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Asfandyar MuftiDivision of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
Jensen YeungDivision of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
University of Toronto · CAHealth Sciences Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a chronic inflammatory skin condition that affects diverse ethnic groups with a wide spectrum of skin colours. There are significant differences in how psoriasis presents and impacts the quality of life in non-White individuals. Genetic variations as well as cultural and socioeconomic factors all play a role in such differences and have important implications for the management of psoriasis in skin of colour. Despite these differences, the current psoriasis management is similar across different ethnic backgrounds and is mainly guided by factors such as disease severity, medical comorbidities and patient preferences. This is largely due to the lack of sufficient evidence for psoriasis treatment tailored for patients with skin of colour as most clinical trials are composed of mainly White individuals. Therefore, the focus of this article is to review the current evidence on how epidemiology, clinical presentation and genetic differences in patients with skin of colour with psoriasis may impact treatment strategies. Additionally, pharmacological therapies available to date in these diverse patient cohorts are summarized in this article. The limited data published on this topic reveal a significant need for more investigations with the ultimate goal of incorporating recommendations for patients with skin of colour into the current guidelines for psoriasis treatment. Moreover, awareness of differences in psoriasis presentation amongst individuals with skin of colour may support patients to seek medical care sooner, which could result in earlier diagnosis and lead to improved patient outcomes.

Indexed as

psoriasisskin of colourtherapeutics

Identifiers

PMID35720056
PMCPMC9165631
OpenAlexW4281820548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.